Are paclitaxel-eluting stents safe and effective in patients with acute coronary syndromes?
J Eduardo Sousa*, Eduardo Missel, Alexandre Abizaid and Amanda Sousa
Correspondence *Institute Dante Pazzanese of Cardiology Interventional Cardiology Avenida Dr Dante Pazzanese, 500, Sao Paulo, 04012-909 Brazil
Email jesousa@uol.com.br
This article has no abstract so we have provided the first paragraph of the full text.
The use of BMSs alongside PCI in complex and vulnerable lesions promoted a significant reduction in ischemic events at 30 days, especially when used with glycoprotein IIb/IIIa inhibitors, as demonstrated in the FRISC II,1 TACTICS2 and RITA-33 trials. Despite these improvements, the frequency of restenosis is still high at 6-month follow-up. Sirolimus-eluting and paclitaxel-eluting polymer-based stents are, therefore, attractive alternatives for overcoming this late adverse outcome. Preliminary data suggest that drug-eluting stents are safe and more effective than BMSs for patients with ACS.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
